Dr. Elizabeth O’Day has over a decade of experience in metabolomics, biochemistry, and precision medicine. She is the CEO and Founder of Olaris Inc., a precision medicine company that leverages the myOLARIS toolbox combining metabolomics, machine learning, and biology to uncover clinical impactful biomarkers that fundamentally change how diseases are treated and diagnosed.
Dr. O’Day serves on the Steering Committee for Scientific American‘s Top 10 Emerging Technologies Council and on the World Economic Forum’s Global Biotechnology Council, where she was the co-Chair. She is also on the Biological Magnetic Resonance Board. Dr. O’Day was recognized as a “change maker” by the White House in 2016 at the United State of Women Summit, a “Next Generation Leader” in biotechnology by the Massachusetts Life Science Center in 2018, one of 19 “Women to Watch” by Women & Wealth magazine in 2019, and as a Hubweek Change Maker in 2019. She was recognized as a 40 under 40 awardee in 2020 by the Boston Business Journal and again in 2023 by the Worcester Business Journal. She was also a Finalist in New England for EY’s Entrepreneur of the Year award in 2021 and 2022.
Dr. O’Day supports the next generation of scientists as adjunct faculty at Boston College, where she has taught metabolism and entrepreneurship. She is also an active angel investor in emerging biotechnology companies through O’Day Capital, LLC.
